SynAct Pharma AB
STO:SYNACT
SynAct Pharma AB
Research & Development
SynAct Pharma AB
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
SynAct Pharma AB
STO:SYNACT
|
Research & Development
-kr49.3m
|
CAGR 3-Years
7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Research & Development
-kr115.7m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Research & Development
-kr91.4m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Research & Development
-kr109m
|
CAGR 3-Years
6%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-7%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Research & Development
-kr3.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-20%
|
|
|
BioArctic AB
STO:BIOA B
|
Research & Development
-kr376.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
SynAct Pharma AB
Glance View
SynAct Pharma AB engages in the development of pharmaceutical drugs for the treatment of inflammatory diseases. The company is headquartered in Lund, Skane. The company went IPO on 2016-07-11. The firm is located in Lund, Sweden. The company develops medicines for acute impairment in inflammatory diseases. The firm's drug candidate AP1189 is intended for the treatment of arthritis including psoriasis arthritis.
See Also
What is SynAct Pharma AB's Research & Development?
Research & Development
-49.3m
SEK
Based on the financial report for Dec 31, 2024, SynAct Pharma AB's Research & Development amounts to -49.3m SEK.
What is SynAct Pharma AB's Research & Development growth rate?
Research & Development CAGR 3Y
7%
Over the last year, the Research & Development growth was 53%. The average annual Research & Development growth rates for SynAct Pharma AB have been 7% over the past three years .
